EUVIMEDEUVIMED entdecken
Vergleichsstudie

Comparative Study of Subcutaneous 6-Month Versus Intramuscular 3-Month Leuprorelin Use in Central Precocious Puberty

Andressa Evaristo Mendanha Lopes iD, Larissa Salomão de Brito, Aline Gasparini Sampaio, Raquel Gomes Lot, Isadora Romanini Brambilla, Raquel Rebouças de Biasi Dias, Jorge Armando Camargo de Oliveira, Alessandra Caivano Rodrigues Ribeiro, Fernanda Castilho Aznar Iajarin, Itatiana Ferreira Rodart, Cristiane Kochi, Carlos Alberto Longui iD

Hormone and Metabolic Research · 01.04.2026 · 58 (04) · 145-151

DOI: 10.1055/a-2771-0527 ↗

Kurz gefasst

Vergleichsstudie in der Zeitschrift Hormone and Metabolic Research, erschienen am 01.04.2026. Verfasst von Andressa Evaristo Mendanha Lopes und 11 weiteren Autor:innen. Beteiligte Einrichtung: Pediatrics, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil. Hauptthemen laut MEDLINE: Leuprolide, Puberty, Precocious.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

This study in central precocious puberty girls receiving gonadotropin-releasing hormone analogues for 18 months aimed to compare leuprorelin biannual (6-mo subcutaneous leuprorelin, group 1, n=13) with the quarterly (3-mo intramuscular leuprorelin, group 2, n=10) on height, pubertal progression, and adverse events.

Methods

Twenty-three girls aged 5.7–9.0 years with median bone age advancement (2.7 y and 2.3 y, respectively) underwent clinical visits every 3 months, including pelvis, breasts and injection site ultrasound and luteinizing hormone measurements 2 hours after and 1 week after gonadotropin-releasing hormone analogue administration. Bone age was determined every 6 months.

Results

Both protocols were able to stop height lost (stabilization of one age adjusted height standard deviation score: group 1=–1.1 to –1.1 and group 2=–0.2 to –0.1, respectively). The difference between bone age and chronological age was significantly reduced in group 1 (p=0.001) and showed a trend in group 2 (p=0.08). The body mass index–standard deviation score remained similar. A decreased breast diameter (p=0.04) and a reduction in uterine volume (p=0.02) were observed in patients from group 1. Local non-inflammatory nodules were identified in groups 1 and 2 (100% and 50%, respectively). Local nodules were larger in group 1 (1.3 vs. 0.1 cm; p=0.03). Luteinizing hormone levels were reduced in all groups, with random luteinizing hormone levels remaining below 0.6 IU/L. Luteinizing hormone values 2 hours after gonadotropin-releasing hormone analogue administration showed a more homogeneous suppressive effect in group 1. Mild to moderate pain was present in both groups, but higher in group 1. Scores for acceptance, easiness and satisfaction were similar between groups.

Conclusions

Six month subcutaneous leuprorelin deaccelerated bone age, preserving the predicted final height in a manner similar to 3-month intramuscular leuprorelin. Only 6-month subcutaneous leuprorelin could reduce uterine and breast volumes. Pain was more prominent with six-month subcutaneous leuprorelin, and drug deposition in the subcutaneous tissue was identified more frequently, without an inflammatory process or a risk of therapeutic failure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LeuprolidePuberty, PrecociousHumansFemaleInjections, IntramuscularInjections, SubcutaneousChildChild, PreschoolPuberty InhibitorsPuberty Suppression

Substanzen

LeuprolidePuberty Inhibitors

Autor:innen und Institutionen

  • Pediatrics, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil.
  • Diagnostic Imaging and Radiology, Irmandade da Santa Casa de Misericordia de São Paulo, São Paulo, Brazil.
  • Physiological Sciences, Faculdade de Ciências Médicas da Santa Casa de São Paulo, São Paulo, Brazil.

ORCID-Profile: Andressa Evaristo Mendanha Lopes, Carlos Alberto Longui

Zitieren

APA

Lopes, A. E. M., Brito, L. S., Sampaio, A. G., Lot, R. G., Brambilla, I. R., Dias, R. R. B., Oliveira, J. A. C., Ribeiro, A. C. R., Iajarin, F. C. A., Rodart, I. F., Kochi, C., & Longui, C. A. (2026). Comparative Study of Subcutaneous 6-Month Versus Intramuscular 3-Month Leuprorelin Use in Central Precocious Puberty. Hormone and Metabolic Research, 58(04), 145-151. https://doi.org/10.1055/a-2771-0527

Vancouver

Lopes AEM, Brito LS, Sampaio AG, Lot RG, Brambilla IR, Dias RRB, et al. Comparative Study of Subcutaneous 6-Month Versus Intramuscular 3-Month Leuprorelin Use in Central Precocious Puberty. Hormone and Metabolic Research. 2026;58(04):145-151. doi:10.1055/a-2771-0527

BibTeX
@article{Lopes2026,
  author = {Lopes, Andressa Evaristo Mendanha and Brito, Larissa Salomão de and Sampaio, Aline Gasparini and Lot, Raquel Gomes and Brambilla, Isadora Romanini and Dias, Raquel Rebouças de Biasi and Oliveira, Jorge Armando Camargo de and Ribeiro, Alessandra Caivano Rodrigues and Iajarin, Fernanda Castilho Aznar and Rodart, Itatiana Ferreira and Kochi, Cristiane and Longui, Carlos Alberto},
  title = {Comparative Study of Subcutaneous 6-Month Versus Intramuscular 3-Month Leuprorelin Use in Central Precocious Puberty},
  journal = {Hormone and Metabolic Research},
  year = {2026},
  volume = {58},
  number = {04},
  pages = {145--151},
  doi = {10.1055/a-2771-0527}
}
Kostenlos starten →